Back to search
IgA Nephropathy (IgAN)
Clinical trial pipeline · Data from ClinicalTrials.gov
See which IgA Nephropathy (IgAN) trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which IgA Nephropathy (IgAN) trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
A study to find how well atacicept works and how safe it is in participants with autoimmune kidney disease.
This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases…
Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that bu…
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
The purpose of the study is to assess the effect of zigakibart on IgA nephropathy (IgAN) disease progression.
In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropathy (IgAN). IgAN is a kidney disease cause…
This is a single-arm, open-label, phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-05, a un…
IgA plays a major role in mucosal and systemic immunity but retains mysterious and ambivalent aspects. They can thus, depending on the situation, prove to be ca…